Centers for Disease Control data shows that diabetes complications including heart attack and amputation fell in the twenty years between 1990 and 2010. The bad news: the number of diagnosed diabetes patients tripled during that same time period.
Healthcare insurers seek to curb diabetes costs with interventions that may include house calls.
Express Scripts said treatments for diabetes are the most expensive of the traditional medications, while specialty drugs are eating up a significant portion of total drug spend.
Researchers found a correlation between patients feeling involved and how well they stick—if they stick—to their medication regimens.
The drugmaker is accused of burying cancer risks associated with the diabetes medication.
The regulator has put off the inhaled insulin's PDUFA date by three months.
The three-year collaboration includes $1.5 million for chronic kidney disease research.
The new indication would mean Tresiba and Victoza could be prescribed in tandem.
The Committee for Medicinal Products for Human Use endorses the SGLT2 inhibitor. The FDA refused to approve the drug earlier this month because of manufacturing issues.
The issue: Boehringer's manufacturing site. The FDA is not asking for new clinical studies.
Spurred by a 2013 report of a possible link between drugs like Merck's Januvia and pancreatitis or pancreatic cancer, the FDA and EMA said they have not found a definitive link but will continue to collect data.
Phase-III results, top-lined today, show Lilly's investigational GLP-1 drug is well-positioned to eat into the multi-billion-dollar diabetes market now dominated by Novo Nordisk.
Merck announced this week that its insulin glargine biosimilar, being developed with Samsung and Biogen Idec, would soon enter Phase-III trials.
Governments have been courting industry investment, reports the Wall Street Journal.
The regulator says a 2013 study that indicated a higher rate of heart failure compared to placebo—but not death—has prompted a second look at the diabetes medication.
A six-month pilot program at the University of Chicago improved glycemic control and engaged patients and HCPs through one key device: a mobile phone.
Constant exchange rates provide a positive framework for quarterly and year-end totals, whereas straight percentages indicate lower sales.
Ten pharma companies will share money and biomarker research under an NIH collaboration.
The suit stalls Eli Lilly's biosimilar version of insulin glargine.
Higher prices helped insulate Q4 and annual sales, which fell and rose 2%, respectively. Lilly said its insulin glargine biosimilar will go nowhere if it is not substantially different from the competition.
The companies are changing the key compound.
Three drug purchasing companies have taken the Denmark drugmaker to court in the US. The charge: wrongfully keeping generics off the market.
AZ's delayed diabetes pill was given the FDA nod today, the second treatment of its kind available in the US behind J&J's Invokana.
The company releases 2014 guidance Tuesday, but signals from the previous 12 months indicate the Indiana drugmaker is determined to hit its $20-billion earnings target, patent losses be damned.
The move to digitize a series of books it co-created with Disney for kids with type 1 diabetes was spurred by a meeting with the online diabetes community.
BMS is giving up its stake of the AstraZeneca diabetes joint venture for $2.7 billion up front, and future milestone payments.
The FDA wants more data for the proposed canagliflozin-metformin medication mix.
The drugmaker and partner AstraZeneca say they can't find a comfortable pricing arrangement with German insurers.
Danish police are investigating the drugmaker over its decision to wait two days before announcing the FDA's February rejection.
FDA panel briefing documents indicate concern remains over bladder cancer, as the drug dapagliflozin undergoes a second review Thursday.